Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040885 · ClinicalTrials.gov registry record · Phase 3
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
A Phase 3 study of Lung Cancer and Fatigue, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 67
- Enrollment target
- 20
- Study locations
NCT00040885 is a Phase 3 study of Lung Cancer and Fatigue that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 67 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT00040885, a Phase 3 study of Lung Cancer and Fatigue, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 67 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Infliximab may improve cancer-related weight loss, lack of appetite, and fatigue. It is not yet known whether docetaxel is more effective with or without infliximab in preventing weight loss and fatigue in patients with advanced cancer. (Infliximab treatment discontinued effective 10/05/05) PURPOSE: Randomized phase III trial to determine the effectiveness of docetaxel with or without infliximab in preventing weight loss, loss of appetite, and fatigue in patients who have unresectable non-small cell lung cancer. (Infliximab treatment discontinued effective 10/05/05)
Conditions Studied
Interventions
- OTHER placebo
- DRUG docetaxel
- BIOLOGICAL infliximab
Study Locations (20)
Colorado
- Aurora Presbyterian Hospital - Aurora
- Boulder Community Hospital - Boulder
- Penrose Cancer Center at Penrose Hospital - Colorado Springs
- Porter Adventist Hospital - Denver
- Presbyterian - St. Luke's Medical Center - Denver
- St. Joseph Hospital - Denver
- Rose Medical Center - Denver
- CCOP - Colorado Cancer Research Program, Incorporated - Denver
- Swedish Medical Center - Englewood
- Sky Ridge Medical Center - Lone Tree
- Hope Cancer Care Center at Longmont United Hospital - Longmont
- St. Mary-Corwin Regional Medical Center - Pueblo
- North Suburban Medical Center - Thorton
Illinois
- Rush-Copley Cancer Care Center - Aurora
- St. Joseph Medical Center - Bloomington
- Graham Hospital - Canton
- Memorial Hospital - Carthage
- Eureka Community Hospital - Eureka
Arizona
- CCOP - Mayo Clinic Scottsdale Oncology Program - Scottsdale
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2002-10 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00040885
The ClinicalTrials.gov registry entry for NCT00040885 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00040885 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Colorado, Illinois, Arizona.
Frequently Asked Questions
What is clinical trial NCT00040885 about?
NCT00040885 is a clinical study titled "Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)". RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Infliximab may improve cancer-related weight loss, lack of appetite, and fatigue. It is not yet known whether docetaxel is more effective with or without in...
What is the current status of trial NCT00040885?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 67 participants. The study started on 2002-10. Estimated completion is 2008-10.
What conditions does trial NCT00040885 study?
This clinical trial studies the following conditions: Lung Cancer, Fatigue, Cachexia, Anorexia.
What interventions are being tested in trial NCT00040885?
The interventions under investigation include: placebo (OTHER), docetaxel (DRUG), infliximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00040885?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00040885 being conducted?
This trial has 20 study locations across Arizona, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
ACTIVE NOT RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.